https://www.cidrap.umn.edu/news-perspective/2022/11/news-scan-nov-03-2022
News Scan for Nov 03, 2022
Northern Hemisphere flu rise;
Support for Uganda Ebola vaccine trials
Filed Under:
Influenza, General;
Ebola;
Viral Hemorrhagic Fever
Flu on the rise in Northern Hemisphere regions, with H3N2 still dominant
Flu activity is starting to rise in parts of the Northern Hemisphere, including Europe and North America, the World Health Organization (WHO) said in its latest global flu update, which covers data through Oct 16.
In central Asia, Kazakhstan reported increased activity, mainly from influenza B. In western Asia, flu rose in some countries, including those on the Arabian Peninsula, and in southern Asia, flu activity remained low, except in Iran.
Tropical African and South American countries reported low flu activity. And while most Southern Hemisphere countries reported further decreases, some temperate South America countries reported increases, including Argentina and Chile.
Of respiratory samples that tested positive for flu at national flu labs during the first half of October, 90.4% were influenza A. Of subtyped influenza A viruses, nearly 82% were H3N2. Of characterized influenza B viruses, all belonged to the Victoria lineage.
Oct 31 WHO global flu update
Groups detail support for Uganda's Ebola vaccine trials
The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, and the WHO today spelled out a plan to speed up research during Uganda's ongoing Ebola outbreak, with a goal of ensuring that the country has access to doses of investigational vaccines against the Sudan Ebola virus.
Currently, there are no licensed vaccines or treatments against Sudan Ebola. Uganda's health ministry recently announced that three candidate vaccines will be tested in the current outbreak setting. They are from Oxford University in the United Kingdom and Sabin Vaccine Institute and Merck in the United States.
In a joint announcement today, the groups also said they would facilitate the scale-up and access to any vaccines that are licensed following the clinical trials, which will be facilitated by Makerere University Lung Institute in Uganda.
Nov 3 CEPI, Gavi, WHO joint statement
News Scan for Nov 03, 2022
Northern Hemisphere flu rise;
Support for Uganda Ebola vaccine trials
Filed Under:
Influenza, General;
Ebola;
Viral Hemorrhagic Fever
Flu on the rise in Northern Hemisphere regions, with H3N2 still dominant
Flu activity is starting to rise in parts of the Northern Hemisphere, including Europe and North America, the World Health Organization (WHO) said in its latest global flu update, which covers data through Oct 16.
In central Asia, Kazakhstan reported increased activity, mainly from influenza B. In western Asia, flu rose in some countries, including those on the Arabian Peninsula, and in southern Asia, flu activity remained low, except in Iran.
Tropical African and South American countries reported low flu activity. And while most Southern Hemisphere countries reported further decreases, some temperate South America countries reported increases, including Argentina and Chile.
Of respiratory samples that tested positive for flu at national flu labs during the first half of October, 90.4% were influenza A. Of subtyped influenza A viruses, nearly 82% were H3N2. Of characterized influenza B viruses, all belonged to the Victoria lineage.
Oct 31 WHO global flu update
Groups detail support for Uganda's Ebola vaccine trials
The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, and the WHO today spelled out a plan to speed up research during Uganda's ongoing Ebola outbreak, with a goal of ensuring that the country has access to doses of investigational vaccines against the Sudan Ebola virus.
Currently, there are no licensed vaccines or treatments against Sudan Ebola. Uganda's health ministry recently announced that three candidate vaccines will be tested in the current outbreak setting. They are from Oxford University in the United Kingdom and Sabin Vaccine Institute and Merck in the United States.
In a joint announcement today, the groups also said they would facilitate the scale-up and access to any vaccines that are licensed following the clinical trials, which will be facilitated by Makerere University Lung Institute in Uganda.
Nov 3 CEPI, Gavi, WHO joint statement